product name Penfluridol
Description: Penfluridol (also known as TLP-607) is a highly potent, first generation diphenylbutylpiperidine antipsychotic. Penfluridol is a neuroleptic drug with long duration of action, which is able to relieve both negative and positive symptoms of schizophrenia. Penfluridol inhibits the binding of dopamine to dopamine receptor with Ki of 1.6 μM. It exerts its antipsychotic activity by blocking the dopamine projections in the limbic system and in mesocortical area.
References: Science. 1976 Apr 30;192(4238):481-3; Proc Natl Acad Sci U S A. 1985 Feb;82(4):1237-41.
523.97
Formula
C28H27ClF5NO
CAS No.
26864-56-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (190.9 mM)
Water: <1 mg/mL
Ethanol: 100 mg/mL (190.9 mM)
Solubility (In vivo)
Synonyms
TLP-607
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19414708
| In Vitro |
In vitro activity: Penfluridol is a neuroleptic drug with long duration of action, which is able to relieve both negative and positive symptoms of schizophrenia. Penfluridol inhibits the binding of dopamine to dopamine receptor with Ki of 1.6 μM. It exerts its antipsychotic activity by blocking the dopamine projections in the limbic system and in mesocortical area. Penfluridol selectively inhibits the binding of [3H]nitrendipine to rat cerebral cortical membrane fraction and also competitively antagonizes potassium-induced calcium-dependent contractions in rat vas deferens. Penfluridol (10 μM) inhibits the contractile response of isolated rings of rabbit thoracic aorta to NE and KCl, and inhibits calcium influx during either NE or KCl stimulation. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Science. 1976 Apr 30;192(4238):481-3; Proc Natl Acad Sci U S A. 1985 Feb;82(4):1237-41. |
